Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

(2020) Jeremy S. Abramson et al.   BLOOD

Interleukin-23 engineering improves CAR T cell function in solid tumors

(2020) Xingcong Ma et al.   NATURE BIOTECHNOLOGY

Recent advances of oncolytic virus in cancer therapy

(2020) Moumita Mondal et al.   Human Vaccines & Immunotherapeutics

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

(2020) Nirali N. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia

(2020) Noelle V. Frey et al.   JOURNAL OF CLINICAL ONCOLOGY

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

(2020) Hanren Dai et al.   Journal of Hematology & Oncology

Tuning the Antigen Density Requirement for CAR T-cell Activity

(2020) Robbie G. Majzner et al.   Cancer Discovery

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

(2020) Lorenzo Galluzzi et al.   Journal for ImmunoTherapy of Cancer

Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15

(2019) Yuhui Chen et al.   CLINICAL CANCER RESEARCH

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

(2019) Jean-Pascal Machiels et al.   Journal for ImmunoTherapy of Cancer

Engineering and Design of Chimeric Antigen Receptors

(2019) Sonia Guedan et al.   Molecular Therapy-Methods & Clinical Development

Cancer immunotherapy with T cells carrying bispecific receptors that mimic antibodies

(2019) Sarah Ahn et al.   Cancer Immunology Research

IL-15-mediated reduction of mTORC1 activity preserves the stem cell memory phenotype of CAR-T cells and confers superior antitumor activity

(2019) Darya Alizadeh et al.   Cancer Immunology Research

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

(2019) Mohamad Hamieh et al.   NATURE

A phase I/II study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: Safety report.

(2019) Maria Pia Morelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure

(2019) Olivia M. Lucero et al.   BRITISH JOURNAL OF HAEMATOLOGY

The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells

(2019) Alexandre V. Hirayama et al.   BLOOD

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy

(2019) Jaco A. C. van Bruggen et al.   BLOOD

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: with an immunotherapeutic effect.

(2019) Yael Chava Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

(2019) Stefan Stoiber et al.   Cells

Rapid Relapse of Large B‐Cell Lymphoma after CD19 Directed CAR‐T‐Cell Therapy due to CD‐19 Antigen Loss

(2019) Ali Bukhari et al.   AMERICAN JOURNAL OF HEMATOLOGY

Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden

(2019) Changju Qu et al.   JOURNAL OF IMMUNOTHERAPY

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

(2019) Bryan D. Choi et al.   NATURE BIOTECHNOLOGY

Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds

(2019) Venkatesh Sivanandam et al.   Molecular Therapy-Oncolytics

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

(2019) Zhiling Yan et al.   Lancet Haematology

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

(2019) Bryan D. Choi et al.   Journal for ImmunoTherapy of Cancer

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

(2019) Noelle V. Frey et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

(2018) Yoshiki Hirooka et al.   BMC CANCER

Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects

(2018) Pavlos Msaouel et al.   CURRENT CANCER DRUG TARGETS

Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma

(2018) Haneen Shalabi et al.   HAEMATOLOGICA

Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside

(2018) Wei Guo et al.   HUMAN GENE THERAPY

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

(2018) Frederick F. Lang et al.   JOURNAL OF CLINICAL ONCOLOGY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?

(2018) Maria C. Ramello et al.   PHARMACOLOGICAL RESEARCH

Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment

(2018) Sujita Sukumaran et al.   Cancer Discovery

Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma

(2018) Haneen Shalabi et al.   HAEMATOLOGICA

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

(2018) Jean-Marc Hoffmann et al.   Frontiers in Immunology

Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene

(2018) Monica Casucci et al.   Frontiers in Immunology

CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation

(2018) Pradip Bajgain et al.   Journal for ImmunoTherapy of Cancer

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

(2018) Sarwish Rafiq et al.   NATURE BIOTECHNOLOGY

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

(2018) Marco Ruella et al.   NATURE MEDICINE

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

(2018) Elena J. Orlando et al.   NATURE MEDICINE

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

(2018) Amanda Rosewell Shaw et al.   Frontiers in Immunology

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

(2018) Jonathan G. Pol et al.   OncoImmunology

Progress in gene therapy using oncolytic vaccinia virus as vectors

(2018) Xue Yang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

(2018) Judith Feucht et al.   NATURE MEDICINE

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

(2018) Susanne H. Baumeister et al.   Cancer Immunology Research

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma

(2018) Xingliang Guo et al.   Frontiers in Pharmacology

CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge

(2018) Sonia Guedan et al.   Frontiers in Immunology

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

(2017) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

(2017) Cameron J. Turtle et al.   JOURNAL OF CLINICAL ONCOLOGY

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

(2017) Jeannette Fischer et al.   JOURNAL OF IMMUNOTHERAPY

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

(2017) A Dispenzieri et al.   LEUKEMIA

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains

(2017) Leah Alabanza et al.   MOLECULAR THERAPY

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer

(2017) Somala Mohammed et al.   MOLECULAR THERAPY

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

(2017) Kevin Bielamowicz et al.   NEURO-ONCOLOGY

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

A versatile system for rapid multiplex genome-edited CAR T cell generation

(2017) Jiangtao Ren et al.   Oncotarget

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

(2017) Levi J. Rupp et al.   Scientific Reports

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

(2017) Oladapo O. Yeku et al.   Scientific Reports

CAR T Cells Releasing IL-18 Convert to T-Bet high FoxO1 low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors

(2017) Markus Chmielewski et al.   Cell Reports

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18

(2017) Biliang Hu et al.   Cell Reports

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants

(2017) Giedre Krenciute et al.   Cancer Immunology Research

Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors

(2017) Alicia M. Waters et al.   Human Gene Therapy Clinical Development

Effect of Modified Vaccinia Ankara–5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer

(2017) Martin Scurr et al.   JAMA Oncology

Oncolytic Viruses in Cancer Treatment

(2017) Sean E. Lawler et al.   JAMA Oncology

Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer

(2017) Anwen Howells et al.   Frontiers in Oncology

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

(2016) R. Gardner et al.   BLOOD

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

(2016) Xiaojun Liu et al.   CANCER RESEARCH

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

(2016) M. V. Maus et al.   CLINICAL CANCER RESEARCH

The myeloma stem cell concept, revisited: from phenomenology to operational terms

(2016) H. E. Johnsen et al.   HAEMATOLOGICA

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

(2016) Meenakshi Hegde et al.   JOURNAL OF CLINICAL INVESTIGATION

High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity

(2016) R C Lynn et al.   LEUKEMIA

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

(2016) Tessa Gargett et al.   MOLECULAR THERAPY

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

(2016) Cameron J. Turtle et al.   Science Translational Medicine

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

(2016) Elad Jacoby et al.   Nature Communications

The myeloma stem cell concept, revisited: from phenomenology to operational terms

(2016) H. E. Johnsen et al.   HAEMATOLOGICA

Fine-tuning the CAR spacer improves T-cell potency

(2016) Norihiro Watanabe et al.   OncoImmunology

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

(2016) Tuuli Ranki et al.   Journal for ImmunoTherapy of Cancer

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia

(2016) Kentaro Minagawa et al.   PLoS One

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Tumor microenvironment: Sanctuary of the devil

(2015) Lanlan Hui et al.   CANCER LETTERS

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

(2015) X. Liu et al.   CANCER RESEARCH

PD-1 Blockers

(2015) Jedd D. Wolchok   CELL

Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model

(2015) H Almåsbak et al.   GENE THERAPY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

(2015) S S Kenderian et al.   LEUKEMIA

Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

(2015) Quan-shun Wang et al.   MOLECULAR THERAPY

Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy

(2015) Mahesh Jonnalagadda et al.   MOLECULAR THERAPY

Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients

(2015) Timothy P Cripe et al.   MOLECULAR THERAPY

First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity

(2015) Herbert J Zeh et al.   MOLECULAR THERAPY

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes

(2015) Ignazio Caruana et al.   NATURE MEDICINE

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo

(2015) Mythili Koneru et al.   OncoImmunology

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer

(2015) L Vassilev et al.   OncoImmunology

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

(2014) E. Galanis et al.   CANCER RESEARCH

A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma

(2014) D. W. Sborov et al.   CLINICAL CANCER RESEARCH

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

(2014) S. Wilkie et al.   JOURNAL OF IMMUNOLOGY

Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults

(2014) Kimberly P Kicielinski et al.   MOLECULAR THERAPY

TroVax in colorectal cancer

(2014) Julie Rowe et al.   Human Vaccines & Immunotherapeutics

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+T-cell response, prominent infiltration of CD8+lymphocytes and Th1 type polarization

(2014) Tuuli Ranki et al.   OncoImmunology

Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

(2013) M. Hudecek et al.   CLINICAL CANCER RESEARCH

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells

(2013) Usanarat Anurathapan et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

(2012) W. Haso et al.   BLOOD

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production

(2012) J. C. Riches et al.   BLOOD

Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice

(2012) D. Chinnasamy et al.   CLINICAL CANCER RESEARCH

Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy

(2012) Sonia Tusell Wennier et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

An NKp30-Based Chimeric Antigen Receptor Promotes T Cell Effector Functions and Antitumor Efficacy In Vivo

(2012) T. Zhang et al.   JOURNAL OF IMMUNOLOGY

Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

(2012) Evanthia Galanis et al.   MOLECULAR THERAPY

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

(2011) M. Chmielewski et al.   CANCER RESEARCH

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer

(2010) E. Galanis et al.   CANCER RESEARCH

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response

(2010) A Hombach et al.   GENE THERAPY

Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4

(2010) Scott Wilkie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Intelligent Design: Combination Therapy With Oncolytic Viruses

(2009) Kathryn Ottolino-Perry et al.   MOLECULAR THERAPY

Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma

(2009) Herschel Wallen et al.   PLoS One

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

(2008) L. Vidal et al.   CLINICAL CANCER RESEARCH

A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas

(2008) Peter Forsyth et al.   MOLECULAR THERAPY